Research Article
Efficacy and Safety of Miltefosine in Treatment of Post-Kala-Azar Dermal Leishmaniasis
Table 1
Hematological and biochemical characteristics of patients at baseline and at 2, 4, and 12 weeks.
| | |
0 week |
2 weeks |
4 weeks |
12 weeks | value | | 0 versus 2 | 0 versus 4 | 0 versus 12 |
| WBC(/L)
Median (IQR) | 8500.00
(6950.00–10600.00) | 9200.00
(7250.00–10300.00) | 9300.00
(7850.00–11000.00) | 8100.00
(6200.00–10900.00) | 0.029 | 0.138 | 0.808 | Hemoglobin (gm/dL)
Median (IQR) | 11.600
(10.100–13.850) | 11.400
(10.500–13.000) | 11.400
(9.900–12.950) | 11.000
(8.650–12.950) | 0.500 | 0.715 | 0.070 | Platelets (/L)
Median (IQR) | 252000
(216000–309000) | 278000
(224000–354000) | 302000
(251500–374000) | 278000
(169000–338000) | 0.013 | 0.009 | 0.955 | BUN (mg/dL)
Median (IQR) | 9.40
(7.17–12.08) | 8.93
(6.28–10.68) | 10.30
(8.58–11.58) | 9.635 (7.050–9.635) | 0.306 | 0.330 | 0.961 | SGOT (IU)
Median (IQR) | 27.00
(19.50–32.50) | 26.00
(20.50–30.50) | 24.00
(10.50–30.50) | 27.00 (16.50–36.00) | 0.617 | 0.206 | 0.851 | SGPT (IU)
Median (IQR) | 31.00
(23.00–37.00) | 28.00
(21.00–39.00) | 29.00
(19.50–48.50) | 23.00 (14.50–34.00) | 0.631 | 0.432 | 0.033 | Serum creatinine (mg/dL)
Median (IQR) | 0.6800
(0.5800–0.8800) | 0.7500
(0.6600–0.9250) | 0.780
(0.650–1.045) | 0.7400
(0.5850–1.0850) | 0.006 | 0.004 | 0.194 |
|
|
IQR: interquartile range.
BUN: blood urea nitrogen.
SGOT: serum glutamic oxaloacetic transaminase.
SGPT: serum glutamic pyruvic transaminase.
|
